Abstract
Nitric oxide (NO) is an important signalling molecule that acts in many tissues to regulate different physiological and pathological processes. We have contributed to demonstrate that NO stimulates angiogenesis and mediates the effect of different angiogenic molecules. In human tumors NOS expression and activity correlate with tumor growth and aggressiveness, through angiogenesis stimulation and regulation of angiogenic factor expression. Drugs affecting the NOS pathway appear promising antitumor strategies by reducing edema, inhibiting angiogenesis and facilitating the delivery of chemotherapeutical agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bakshi A., Nag T.C., Wadhwa S., Mahapatra A.K., Sarkar C. The expression of nitric oxide in human brain tumors and peritumoral areas. J Neurol Sci 1998; 15: 196–203.
Bian X., Du L., Chen Z., Shi J., Liu F. A quantitative pathological study on angiogenesis, vascular endothelial growth factor and inducible nitric oxide synthase in astrocytomas. Zhonghua Bing Li Xue Za Zhi. 2001; 30:23–6.
Bing R.J., Miyataka M., Rich K.A., Hanson N., Wang X., Slosser H.D., Shi S.R. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin Cancer Res. 2001; 7:3385–92.
Broholm H., Braendstrup O., Lauritzen M. Nitric oxide synthase expression of oligodendrogliomas. Clin Neuropathol. 2001; 20:233–8.
Cheshire D.R. Use of nitric oxide synthase inhibitors for the treatment of inflammatory disease and pain. Drugs 2001; 4: 795–802.
Chiou W.F., Chou C.J., Chen C.F. Camptothecin suppresses nitric oxide biosynthesis in RAW 264.7 macrophages. Life Sci. 2001; 69: 625–35.
Cobb J.P. Use of nitric oxide synthase inhibitors to treat septic shock: The light has changed from yellow to red. Crit Care Med 1999; 27: 855–6.
Cobbs C.S., Brenman J.E., Alpade K.D., Bredt D.S., Israel M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995; 55: 727–30.
Cook J.A., Krishna M.C., Pacelli R., DeGraff W., Liebmann J., Mitchell J.B., Russo A., Wink D.A. Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 1997; 76:325–34.
Dawson T.M., Sasaki M., Gonzalez-Zulueta M., Dawson V.L. Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Prog Brain Res. 1998; 118: 3–11.
de Wilt J.H., Manusama E.R., van Etten B., van Tiel S.T., Joma A.S., Seynhaeve A.L., ten Hagen T.L., Eggermont A.M. Nitric oxide synthase inhibition results in synergistic antitumor activity with melphalan and tumor necrosis factor alpha-based isolated limb perfusions. Br J Cancer. 2000; 83:1176–82.
Doi K., Akaike T., Horie H., Noguchi Y., Fuji S., Beppu T., Ogawa M., Maeda H. Excessive production of NO in rat solid tumor and its implication in rapid tumor growth. Cancer 1996; 77:1598–1604.
Ellie E., Loiseau H., Lafond F., Arsaut J., Demotes-Mainard J. Differential expression of inducible nitric oxide synthase in human brain tumors. Neuroreport 1995; 7: 294–6.
Farias-Eisner R., Chaudhuri G., Aeberhard E., Fukuto J.M. The chemistry and tumoricidal activity of nitric oxide/hydrogen peroxide and the implications to cell resistance/susceptibility. J Biol Chem 1996; 271:6144–51.
Feng C., Wang L., Jiao L., Liu B., Zheng S., Xie X. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2002; 2(1):8.
Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–4.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995; 1:27–31.
Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–63.
Franchi A., Gallo O., Paglierani M., Sardi I., Magnelli L., Masini E., Santucci M. Inducible nitric oxide synthase expression in laryngeal neoplasia: correlation with angiogenesis. Head Neck. 2002; 24:16–23.
Fricker S.P. Nitrogen monoxide-related disease and nitrogen monoxide scavengers as potential drugs. Met Ions Biol Syst. 1999; 36: 665–721.
Fricker S.P., Slade E., Powell N.A., Vaughan O.J., Henderson G.R., Murrer B.A., Megson I.L., Bisland S.K., Flitney F.W. Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases. Br J Pharmacol 1997, 122: 1441–9.
Fujisawa H., Ogura T., Hokari A., Weisz A., Yamashita J., Esumi H. Inducible nitric oxide synthase in a human glioblastoma cell line. J Neurochem 1995; 64:85–91.
Fukumura D., Yan F., Endo M., Jain R.K. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 1997; 150:713–25.
Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W.A., Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998; 90: 587–96.
Garbossa D., Fontanella M., Pagni C.A., Vercelli A. Nitric oxide synthase and cytochrome c oxidase changes in the tumoral and peritumoral cerebral cortex. Acta Neurochir (Wien) 2001; 143:897–908.
Garvey E.P., Oplinger J.A., Furfine E.S., Kiff R.J., Laszlo F., Whittle B.J., Knowles R.G. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997; 272:4959–63.
Hara E., Takahashi K., Tominaga T., Kumabe T., Kayama T., Suzuki H., Fujita H., Yoshimoto T., Shirato K., Shibahara S. Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors. Biochem Biophys Res Commun 1996; 224:153–8.
Hood J.D., Ziche M., Granger H.G. VEGF upregulates ecNOS message, protein, and NO production. Am J Physiol 1998; 274: H1054–8.
Hurst R.D., Clark J.B. Nitric oxide-induced blood-brain barrier dysfunction is not mediated by inhibition of mitochondrial respiratory chain activity and/or energy depletion. Nitric Oxide 1997; 1:121–9.
Iwata S., Nakagawa K., Harada H., Oka Y., Kumon Y., Sakaki S. Endothelial nitric oxide synthase expression in tumor vasculature is correlated with malignancy in human supratentorial astrocytic tumors. Neurosurgery 1999; 45:24–8.
Jadeski L.C., Lala P.K. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999; 155:1381–90.
Johansson A.C., Hegardt P., Janelidze S., Visse E., Widegren B., Siesjo P. Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNgamma secreting rat glioma cells. J Neuroimmunol 2002; 123:135–43.
Kennovin G.D., Hirst D.G., Stratford M.R.L., Flitney F.W. Inducible nitric oxide synthase is expressed in tumor-associated vasculature: inhibition retards tumors in vivo. In Biology on Nitric Oxide. Vol 4, Enzymology, biochemistry, and immunology, pp. 473–479, Eds Moncada S., Feelisch M., Busse R. Higgs A.E., Portland Press, London, 1994.
Kerwin J.F. Jr., Lancaster J.R. Jr., Feldman P.L. Nitric oxide: A new paradigm for second messengers. J Med Chem 1995; 38: 4343–62.
Klotz T., Bloch W., Volberg C., Engelmann U., Addicks K. Selective expression of inducible nitric oxide synthase in human prostatic carcinoma. Cancer 1998; 82: 1897–903
Knowles R.G., Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298:249–5 8.
Kong G., Kim E.K., Kim W.S., Lee Y.W., Lee J.K., Paik S.W., Rhee J.C., Choi K.W., Lee K.T. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer. Int J Pancreatol 2001; 29:133–40.
Ludwig H.C., Ahkavan-Shigari R., Rausch S., Schallock K., Quentin C., Ziegler D., Bockermann V., Markakis E. Oedema extension in cerebral metastasis and correlation with the expression of nitric oxide synthase isozymes (NOS I-III). Anticancer Res 2000a; 20:305–10.
Ludwig H.C., Feiz-Erfan I., Bockermann V., Behnke-Mursch J., Schallock K., Markakis E. Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas. Anticancer Res 2000b; 20:299–304.
Marietta M.A. Nitric oxide synthase structure and mechanism. J Biol Chem 1993; 268: 12231–4.
Marrogi A.J., Travis W.D., Welsh J.A., Khan M.A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N.E., Liotta L.A., Harris C.C. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6:4739–44.
Mitchell J.B., Cook J.A., Krishna M.C., DeGraff W., Gamson J., Fisher J., Christodoulou D., Wink D.A. Radiation sensitisation by nitric oxide releasing agents. Br J Cancer Suppl. 1996; 27:S181–4.
Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., Krishna M.C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993; 53:585–8.
Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–12.
Morbidelli L., Chang C.-H., Douglas J.G., Granger H.J., Ledda F., Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium Am J Physiol 1996; 270: H411–5.
Morbidelli L., Donnini S., Mitola S., Ziche M. Nitric oxide modulates the angiogenic phenotype of middle-t transformed endothelial cells. Int J Biochem Cell Biol 2001; 33: 305–13.
Mosi R., Seguin B., Cameron B., Amankwa L., Darkes M.C., Fricker S.P. Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger. Biochem Biophys Res Commun 2002; 292: 519–29.
Orucevic A., Lala P.K. NG-nitroL-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumor growth in adenocarcinoma-bearing mice. Br J Cancer 1996; 73: 189–96.
Parenti A., Morbidelli L., Cui X.L., Douglas J.G., Hood J., Granger H.J., Ledda F., Ziche M. Nitric oxide is an upstream signal for vascular endothelial growth factor-induced extracellular signal-regulated kinases’/z activation in postcapillary endothelium. J Biol Chem 1998; 273: 4220–6.
Parenti A., Morbidelli L., Ledda F., Granger H.J., Ziche M. The bradykinin/B1 receptor promotes angiogenesis by upregulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 2001; 15: 1487–9.
Parkins C.S., Holder A.L., Hill S.A., Chaplin D.J., Tozer G.M. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 2000; 83: 811–6.
Parratt J.R. Nitric oxide. A key mediator in sepsis and endotoxaemia? J Physiol Pharmacol 1997; 48: 493–506.
Pritchard R., Flitney F.W., Darkes M.A., Fricker, S.P. Ruthenium-based nitric oxide scavengers inhibit tumor growth by reducing tumor vasculature. Clin Exp Metast 1999; 17:776.
Rudic R.D., Shesely E.G., Maeda N., Smithies O., Segal S.S., Sessa W.C. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodelling. J Clin Invest 1998; 101: 731–6.
Salom J.B., Orti M., Centeno J.M., Torregrosa G., Alborch E. Reduction of infarct size by the NO donors sodium nitroprusside and spermine/NO after transient focal cerebral ischemia in rats. Brain Res 2000; 865: 149–56.
Shinoda J., Whittle I.R. Nitric oxide and glioma: a target for novel therapy? Br J Neurosurg 2001; 15: 213–20.
Swaroop G.R., Kelly P.A., Bell H.S., Shinoda J., Yamaguchi S., Whittle I.R. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology. Br J Neurosurg 2000; 14:543–8.
Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 1995; 3: 2–32.
Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynaecological cancer. Cancer Res 1994; 54: 1352–4.
Thomsen L.L., Scott J.M.J., Topley P., Knowles R.G., Keerie A.J., Frend A.J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo. Studies with 1400 W, a novel inhibitor. Cancer Res 1997; 57: 3300–4.
Titheradge M.A. Nitric oxide in septic shock. Biochem Biophys Acta 1999; 1411: 437–55
Tozer G.M., Prise V.E., Chaplin D.J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1997; 57: 948–55.
Uotila P., Valve E., Martikainen P., Nevalainen M., Nurmi M., Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001; 29: 23–8.
Verovski V.N., Van den Berge D.L., Soete G.A., Bols B.L., Storme G.A. Intrinsic radio-sensitivity of human pancreatic tumor cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br J Cancer 1996; 74: 1734–42.
Wink DA, Vodovotz Y, Cook JA, Krishna MC, Kim S, Coffin D, DeGraff W, Deluca AM, Liebmann J, Mitchell JB. The role of nitric oxide chemistry in cancer treatment. Biochemistry (Mosc). 1998a;63(7):802–9.
Wink D.A., Vodovotz Y., Laval J., Laval.F, Dewhirst M.W., Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Cancerogenesis 1998b; 19: 711–21.
Xie K., Huang S., Dong Z., Juang S.-H., Wang Y., Fidler I.J. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997; 89: 421–7.
Zhang X.M., Xu Q. Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of inununocytes. Melanoma Res 2001; 11: 559–67.
Ziche M., Morbidelli L. Nitric oxide and angiogenesis J Neuro Oncology 2000; 50: 13948.
Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997a; 99: 2625–34.
Ziche M., Morbidelli L., Donnini S. Angiogenesis. Exp. Nephrology, 1996; 4:1–14.
Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., Geppetti P., Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94: 2036–44.
Ziche M., Morbidelli L., Parenti A., Amerini S., Granger H.J., Maggi C.A. Substance P increases cyclic GMP levels on coronary postcapillary venular endothelial cells. Life Sci 1993; 53: 1105–12.
Ziehe M., Parenti A., Ledda F., Dell’Era P., Granger H.J., Maggi C.A., Presta M. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Cire Res 1997b; 80: 845–52.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Morbidelli, L., Donnini, S., Ziche, M. (2004). Role of Nitric Oxide in Tumor Angiogenesis. In: Kirsch, M., Black, P.M. (eds) Angiogenesis in Brain Tumors. Cancer Treatment and Research, vol 117. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8871-3_11
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8871-3_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4699-9
Online ISBN: 978-1-4419-8871-3
eBook Packages: Springer Book Archive